Back to top

MANUFACTURING AND SUPPLY AGREEMENT

Requirements Supplier Agreement

MANUFACTURING AND SUPPLY AGREEMENT | Document Parties: AAIPHARMA INC You are currently viewing:
This Requirements Supplier Agreement involves

AAIPHARMA INC

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.
Title: MANUFACTURING AND SUPPLY AGREEMENT
Governing Law: Georgia     Date: 6/15/2004
Industry: Biotechnology and Drugs     Sector: Healthcare

50 of the Top 250 law firms use our Products every day

 

<PAGE>

                                                                   EXHIBIT 10.22

 

 

                       MANUFACTURING AND SUPPLY AGREEMENT

 

         THIS MANUFACTURING AND SUPPLY AGREEMENT (the "Supply Agreement") is

made and entered into as of July 16, 2003 (the "Effective Date"), by and between

aaiPharma Inc. ("AAI") and Mikart, Inc. ("Manufacturer"). Manufacturer and AAI

may be referred to herein individually as a "Party" and collectively as the

"Parties". Manufacturer is a Georgia corporation with its principal place of

business at 1750 Chattahoochee Avenue, Atlanta, Georgia 30318. AAI is a Delaware

corporation with its principal place of business at 2320 Scientific Park Drive,

Wilmington, North Carolina 28405.

 

                                    BACKGROUND:

 

         Manufacturer has, contemporaneously with the execution of this Supply

Agreement, entered into an asset purchase agreement with Athlon Pharmaceuticals,

Inc. ("Athlon") pursuant to which Manufacturer has assigned to Athlon its entire

right, title and interest in and to the Product (as defined below) and the ANDA

(the "Manufacturer/Athlon Agreement");

 

         Athlon has, contemporaneously with the execution of this Supply

Agreement, entered into an asset purchase agreement with AAI pursuant to which

Athlon has assigned to AAI its entire right, title and interest in and to the

Product and the ANDA (the "Athlon/AAI Agreement");

 

         AAI desires to engage Manufacturer to become qualified to Manufacture,

and to Manufacture as of the approval of the ANDA for the Product by the FDA

(the "Product Approval Date") for subsequent commercial distribution by AAI on

the terms and conditions set forth herein; and

 

         Manufacturer wishes to Manufacture the Product for AAI on the terms and

conditions set forth herein.

 

         NOW THEREFORE, for and in consideration of the premises and mutual

covenants contained herein, the Parties agree as follows:

 

                                    ARTICLE 1

                                   DEFINITIONS

 

         The following words, terms and phrases, when used herein, shall have

the following respective meanings:

 

         1.1 "ANDA" shall mean ANDA #76-429 with respect to the Product.

 

         1.2 "API" shall mean the active pharmaceutical ingredient with respect

to the Product.

 

         1.3 "Affiliate" of a Party shall mean any entity that is directly or

indirectly controlled by a Party; directly or indirectly controls a Party; or is

under common control with a Party.

 

 

<PAGE>

 

         1.4 "Batch" shall mean 1,080,000 tablets of the Product produced in a

contiguous process or series of processes that is expected to be homogeneous and

that meets the Specifications. To the extent Manufacturer modifies its equipment

or obtains additional equipment to allow for greater capacity, the Parties agree

to negotiate in good faith to enable an increase in the permitted batch size

under this Section 1.4.

 

         1.5 "Contract Year" shall mean the period beginning on the Supply Start

Date and ending on the last day of the calendar month that contains the one year

anniversary of the Supply Start Date, and each twelve month period thereafter

during the term of this Supply Agreement.

 

         1.6 "CGMP" means the FDA's current Good Manufacturing Practice

requirements as promulgated under the FFDCA at 21 CFR (parts 210 and 211), and

as further defined by FDA guidance documents and rules and regulations

administered by the FDA, as such may be amended from time to time.

 

         1.7 "CGMP Requirements" means the requirements of the CGMP.

 

         1.8 "COGS" shall be as defined in Section 8.2 hereof.

 

         1.9 "DEA" means the United States Drug Enforcement Agency, and any

successor agency or entity thereto that may be established hereafter.

 

         1.10 "Drug Application" shall mean the ANDA and any other governmental

or regulatory consents, registrations, approvals or permits necessary to sell or

Manufacture the Product in the United States.

 

         1.11 "FDA" shall mean the United States Food and Drug Administration or

any successor agency thereof.

 

         1.12 "FFDCA" means the Federal Food, Drug, and Cosmetic Act, 21

U.S.C.ss.ss. 301 et seq., as such may be amended from time to time.

 

         1.13 "Law" means any federal, state or local law, statute or ordinance,

or any rule or regulation promulgated by domestic governmental or regulatory

authorities, including the FDA and DEA.

 

         1.14 "Manufacture" and "Manufacturing" means the manufacturing,

processing, formulating, packaging, labeling, holding and quality control and

other testing of the Product to be performed prior to delivery to AAI or AAI's

designee by Manufacturer.

 

         1.15 "Product" means one hundred (100) count tablet bottles of

Propoxyphene Napsylate 100mg and Acetaminophen 500mg pharmaceutical product.

 

         1.16 "Qualification Date" shall mean the date on which Manufacturer

satisfactorily completes its validation and testing of the Product pursuant to

Article 3 of this Supply

 

 

                                       2

<PAGE>

 

Agreement such that it becomes authorized to begin Manufacturing the Product

under the Drug Application in accordance with the terms of this Supply

Agreement.

 

         1.17 "Quality Agreement" means an agreement between the Parties which

describes certain quality and regulatory responsibilities relating to the

Manufacture and release for sale of the Product by Manufacturer to AAI. The

initial Quality Agreement is attached hereto as Exhibit A and is incorporated

herein by reference. The Quality Agreement will be subject to and not

inconsistent with the terms of this Supply Agreement, and in the event of

conflict between terms of this Supply Agreement, on one hand, and the Quality

Agreement on the other, this Supply Agreement will govern. The Quality Agreement

may be modified from time to time through the issuance of a revised Quality

Agreement signed on behalf of each of the Parties by an authorized

representative incorporating the modification and stating the effective date and

revision number of the modification.

 

         1.18 "Raw Materials" means any excipient and component materials used

to Manufacture the Product, but excluding the API.

 

         1.19 "Specifications" means the test and acceptance criteria for

manufacturing, packaging and testing the Product, raw materials and API as set

forth in the Drug Application.

 

         1.20 "Supply Start Date" shall be as defined in Section 4.1.

 

         1.21 "Term" shall mean the Initial Term plus any Renewal Terms, as such

terms are defined in Section 11.1 hereof.

 

         1.22 "United States" means the fifty (50) states comprising the United

States of America, the District of Columbia and all territories and possessions

of the United States of America.

 

                                    ARTICLE 2

                                PRE-PRODUCT LAUNCH

 

         2.1 Product Launch Planning. The Parties agree to cooperate in good

faith to prepare for the launch of the Product to take place as soon as

reasonably practicable after the Product Approval Date. The Parties agree to

develop appropriate timelines for each phase of the launch of the Product and

shall cooperate in good faith in pursuing all issues related to the approval of

the ANDA by the FDA.

 

         2.2 Notification to FDA. Upon execution of this Agreement, the

Manufacturer/Athlon Agreement and the Athlon/AAI Agreement, Manufacturer will

submit to the FDA a change in ownership letter pursuant to 21 C.F.R. 314.72 with

respect to the transfer of the ANDA to AAI in the form set forth in Exhibit B

attached hereto, and the Parties agree to cooperate in good faith and to take

such actions as are reasonably necessary to reflect such change of ownership of

the ANDA to AAI. In addition, Manufacturer will deliver to AAI within ten (10)

business days after the Effective Date the Drug Application and all supporting

documentation. AAI shall use commercially reasonable efforts to obtain approval

of the ANDA

 

 

                                       3

<PAGE>

 

for the Product from the FDA and shall not take any action with respect to the

ANDA which would impair the ability of or the potential for the Parties to

perform their respective obligations hereunder. In addition, once approved by

the FDA, AAI shall not withdraw the ANDA unless required to do so by the FDA.

 

         2.3 Product Formulations and Specifications. AAI shall provide

Manufacturer with the formulations and Specifications for the Product as set

forth in the Drug Application or as otherwise permitted by the FDA.

 

                                    ARTICLE 3

                              VALIDATION AND TESTING

 

         3.1 Validation and Quota. Manufacturer shall use its commercially

reasonable efforts to become authorized as of the Product Approval Date to

Manufacture the Product under the Drug Application as contemplated herein. To

accomplish the same, Manufacturer shall conduct validation on Batches of Product

until it has manufactured three (3) sequential Batches of the Product that

conform to the specifications and are otherwise in compliance with the terms of

this Agreement (such three (3) Batches being referred to as "Commercial

Validation Batches"). AAI shall be obligated to purchase the Commercial

Validation Batches in accordance with the terms of this Supply Agreement. Such

Commercial Validation Batches shall be part of, and shall be applied to, AAI's

minimum purchase requirements as set forth in Section 7.3 hereof. Manufacturer

will utilize its commercially reasonable efforts to become qualified to

Manufacture the Product as soon as reasonably practicable after the Effective

Date and AAI shall provide reasonable technical assistance to Manufacturer to

enable Manufacturer to become so qualified.

 

         3.2 Drug Application. AAI shall be responsible for maintaining the Drug

Application in full force and effect at all times; provided, however, upon the

reasonable request of AAI, Manufacturer shall reasonably assist AAI, at

Manufacturer's expense, in connection therewith. Manufacturer hereby

acknowledges and agrees that the Drug Application will be owned by, in the name

of and for the benefit of AAI and that Manufacturer has no rights in or to the

Drug Application.

 

                                    ARTICLE 4

                                   MANUFACTURE

 

         4.1 Manufacture. As of the later of the Product Approval Date and

Qualification Date (the "Supply Start Date") and thereafter during the Term, but

subject to Article 7 hereof, AAI will purchase exclusively from Manufacturer one

hundred percent (100%) of AAI's future requirements for Product for resale in

the United States, and Manufacturer shall Manufacture and supply such Product

for and to AAI. Subject to the terms and conditions contained herein,

Manufacturer shall Manufacture all Product to be delivered to AAI or AAI's

designee (a) in accordance with the Drug Application, Specifications, the

Quality Agreement and this Supply Agreement and (b) in material compliance with

the CGMP Requirements and all other legal requirements applicable to the

Manufacturing and supplying of Product to be marketed and sold by AAI. In the

event AAI desires to market, distribute or sell the Product in any territory

other than the United States (each, a "Foreign Territory"), then the Parties

agree to negotiate in good

 

 

                                       4

<PAGE>

 

faith and for a reasonable period of time to enable the Manufacturer to

Manufacture the Product exclusively for AAI in such Foreign Territory.

 

         4.2 Exclusivity. Manufacturer shall Manufacture and sell Propoxyphene

Napsylate 100mg and Acetaminophen 500 mg pharmaceutical product exclusively for

and to AAI during the Term.

 

         4.3 Manufacturer Changes. Except as otherwise provided in this Section

4.3, Manufacturer may not change the Specifications or Manufacturing process for

the Product or the source(s) of API or Raw Materials without the prior written

consent of AAI, which consent shall not be unreasonably withheld or delayed.

Changes made to comply with official or compendial revisions will be made and

implemented by Manufacturer on or before the published effective date for such

changes, and require neither advance notice to nor approval by AAI; provided,

however, that Manufacturer agrees to include such changes in the Product annual

report.

 

         4.4 AAI Requested Changes. Manufacturer shall make such changes as are

reasonably practicable to the Manufacturing process if requested in writing by

AAI, including, but not limited to, changes to the Product, Specifications, API

or Raw Materials related to the Product; provided, however, that such changes

comply with applicable Law, are consistent with the Drug Application and can be

reasonably implemented by Manufacturer.

 

         4.5 Notification and Costs of Changes. Manufacturer shall identify for

AAI, in writing prior to delivery, the first manufactured Batch of any Product

for which changes have been implemented pursuant to Section 4.3 or 4.4 hereof,

and will expressly identify the changes. Any and all direct costs and expenses

associated with all changes shall be borne by the Parties as follows: (i) AAI

shall bear all direct costs and expenses with respect to changes requested by

AAI, but which are not required by applicable Law; (ii) Manufacturer shall bear

all direct costs and expenses with respect to changes requested by Manufacturer,

but which are not required by applicable Law; and (iii) the Parties agree to

negotiate in good faith to determine an appropriate allocation of the costs and

expenses associated with changes required by applicable Law.

 

         4.6 Amendment of Specifications. If a change is made to the

Specifications, AAI shall be responsible for amending the Drug Application for

the Product, if required, to reflect such change, and obtaining required FDA

approval of such amendment, if any. Manufacturer shall, at AAI's expense, use

commercially reasonable efforts to assist AAI in obtaining any such approvals.

 

         4.7 Labeling. AAI shall specify all labeling to be used on the Product

and the packaging thereof, including any changes or modifications to such

labels. Manufacturer shall order labels from time to time in sufficient

quantities to permit the labeling of Product ordered by AAI from time to time

hereunder. The Manufacturer agrees to use the specified labeling (and only such

labeling) on the Product, and not to use such labeling on any other product. Any

AAI directed change or modification to a Product label shall be implemented by

the Manufacturer (i) as soon as reasonably practicable if required by Law, or

(ii) as soon as reasonably practicable, but no later than twenty-six (26) weeks,

following Manufacturer's receipt of notification of such label changes if not

required by applicable Law. Except where the labeling change is a result of

 

 

                                       5

<PAGE>

 

a change required or requested by Manufacturer, AAI shall reimburse the

Manufacturer for costs incurred in connection with any such label change,

including without limitation, the costs of obsolescence of goods-in-process,

packaging materials and supplies, and finished goods not suitable for marketing,

but only to the extent that such items relate to or were acquired to satisfy a

Firm Commitment. AAI shall own all proprietary information included on the

labels for the Product. Notwithstanding anything to the contrary in this Section

4.7, all costs and expenses associated with labeling, tooling and artwork shall

be the responsibility of AAI.

 

         4.8 Raw Materials and API. The Manufacturer shall purchase at its own

expense and for its own account all Raw Materials, API, packaging components and

other items of any nature whatsoever that the Manufacturer may use to

Manufacture the Product. Except as otherwise agreed to between the Parties, all

right, title and interest in and to these items, and in and to all

work-in-process incorporating these items, shall remain the sole property of the

Manufacturer until Product incorporating such items is delivered to AAI;

provided, that AAI shall reimburse the Manufacturer for out-of-pocket-costs

associated with write-offs, obsolescence and/or destruction of finished

inventory resulting from any change or modification to any Product Manufacturing

process, Specifications, Registration or labeling requested by AAI or required

by a change in applicable Law, but only to the extent such Raw Materials, API

and other items relate to or were acquired to satisfy a Firm Commitment.

 

                                    ARTICLE 5

                         REPRESENTATIONS AND WARRANTIES

 

         5.1 Representations and Warranties of Manufacturer. Manufacturer hereby

represents and warrants to AAI as follows:

 

                  (a) Authorization. Manufacturer has full power and authority

to execute, deliver and perform this Supply Agreement and to consummate the

transactions contemplated hereby; this Supply Agreement has been duly executed

and delivered by Manufacturer and constitutes the valid and binding obligation

of Manufacturer, enforceable against Manufacturer in accordance with its terms,

except as enforceability may be limited by bankruptcy, insolvency,

reorganization, moratorium and other laws relating to creditors' rights,

generally.

 

                  (b) Absence of Conflicts. The execution, delivery and

performance of this Supply Agreement by Manufacturer does not conflict with or

constitute a default under any agreement, instrument or understanding, oral or

written to which they are a party or by which they may be bound, does not

conflict with any provision of any organizational document of Manufacturer and

does not conflict with or violate any applicable Law.

 

                  (c) Organization and Standing. Manufacturer is duly organized,

validly existing and in good standing under the Laws of the State of Georgia.

 

                  (d) Actions. As of the Effective Date, there are no pending or

uncorrected citations or adverse conditions noted in any inspection of the

production facilities to be employed for the Manufacture of the Product that

would materially interfere with Manufacturer's Manufacture and supply of the

Product to AAI.

 

 

                                        6

<PAGE>

 

                  (e) Debarment. Pursuant to Section 306(k) of the FFDCA as

amended by the Generic Drug Enforcement Act of 1992, Manufacturer is not

debarred, has not, and will not, use in any capacity in connection with this

Supply Agreement, the services of any person debarred under subsection (a) or

(b) of the Generic Drug Enforcement Act of 1992. Additionally, during the

previous five (5) years, neither Manufacturer nor any affiliated person has been

convicted of the offenses described in sub-section (a) or (b) of the Generic

Drug Enforcement Act of 1992.

 

                  (f) Compliance With Laws. Manufacturer shall comply with Laws

applicable to its operations; and any and all hazardous and toxic waste, if any,

will be manifested and discarded as required by applicable Laws.

 

                  (g) Product. All Product delivered by the Manufacturer (or any

subcontractor thereof) will at delivery be (i) in compliance with this Supply

Agreement, the Quality Agreement, the Drug Application and the Specifications

and (ii) in compliance with all applicable Laws and the CGMP Requirements; (iii)

not be adulterated within the meaning of the FFDCA or within the meaning of any

other applicable Law.

 

                  (h) Manufacturer assigned to Athlon on the Effective Date its

entire right, title and interest in and to the Product and the ANDA (and all

documents related thereto), excluding any of the Manufacturer Intellectual

Property, free and clear of all liens and encumbrances.

 

         5.2 Warranties of AAI. AAI hereby warrants and represents to the

Manufacturer as follows:

 

                  (a) Authorization. AAI has full company power and authority to

execute, deliver and perform this Supply Agreement and to consummate the

transactions contemplated hereby; this Supply Agreement has been duly executed

and delivered by AAI and constitutes the valid and binding obligation of AAI,

enforceable against AAI in accordance with its terms except as enforceability

may be limited by bankruptcy, insolvency, reorganization, moratorium and other

Laws relating to or affecting creditors' rights generally.

 

                  (b) Absence of Conflict. The execution, delivery and

performance of this Supply Agreement by AAI does not conflict with or constitute

a default under any agreement, instrument or understanding, oral or written, to

which it is a party or by which it may be bound, does not conflict with any

provision of any organizational document of AAI and does not conflict with or

violate any applicable Law;

 

                  (c) Organization and Standing. AAI is a corporation, duly

organized, validly existing and in good standing under the Laws of Delaware;

 

                  (d) Title and Authority. AAI has full right, title and

interest in and to the Drug Application and, except with respect to the

Manufacturer Intellectual Property, has the full power and authority to grant to

Manufacturer the right to Manufacture and supply the Product under the Drug

Application;

 

 

                                        7

<PAGE>

 

                  (e) Intellectual Property. AAI has the full power and

authority to grant to Manufacturer the right to use the AAI Intellectual

Property (as hereinafter defined); and

 

                  (f) Infringement. To AAI's knowledge, the Manufacture of

Product in accordance with the Specifications does not and will not infringe any

patent or other intellectual property right of any third party.

 

         5.3 Limitation of Liability. EXCEPT FOR AMOUNTS THAT MAY BECOME PAYABLE

PURSUANT TO SECTION 13.2(b) OR SECTION 7.3, NEITHER MANUFACTURER NOR AAI OR

THEIR RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR

CONSEQUENTIAL DAMAGES (INCLUDING FOR LOST PROFITS), WHETHER IN CONTRACT,

WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR

RELATING TO THIS SUPPLY AGREEMENT, WHETHER OR NOT ADVISED OF THE POSSIBILITY OF

SUCH DAMAGES; EXCEPT AS EXPRESSLY PROVIDED IN THIS SUPPLY AGREEMENT, NEITHER

PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, EITHER IN FACT

OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY

DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES, INCLUDING ANY IMPLIED

WARRANTY OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE,

WARRANTY OF TITLE AND WARRANTY OF NON-INFRINGEMENT.

 

                                    ARTICLE 6

                                QUALITY ASSURANCE

 

         6.1 Quality Agreement. The respective quality assurance obligations of

Manufacturer and AAI are more fully set forth in the Quality Agreement.

 

         6.2 Manufacturer's Covenants. Manufacturer hereby covenants during the

Term that it shall:

 

                  (a) have and maintain the necessary expertise, personnel,

facilities, permits, licenses and equipment to Manufacture the Product in

accordance with, and to perform its other obligations arising under or out of,

this Supply Agreement;

 

                  (b) operate and maintain its premises, plant and machinery,

equipment and procedures related to the Product in compliance with applicable

CGMP Requirements;

 

         6.3 Testing Requirements, Retained Samples.

 

                  (a) At least five (5) business days prior to the shipment of

Product hereunder, Manufacturer shall provide to AAI a certificate of analysis

(each a "COA") with respect to the Product to be shipped. AAI must respond in

writing within three (3) business days following receipt of the applicable COA

if AAI disputes or objects to any information reflected in the COA. The Parties

shall cooperate in good faith to resolve any issues raised by AAI in such

written response, if any, in order to enable shipment of the Product on the

scheduled Product shipment date. If the Parties are unable to resolve such

issues to enable shipment of the Product

 

 

                                       8

<PAGE>

 

on the scheduled Product shipment date, the Parties agree to cooperate in good

faith to reschedule the shipment of the Product as soon as reasonably

practicable. For the avoidance of doubt but subject to AAI's rights pursuant to

Article 9 of this Supply Agreement, if AAI does not respond in writing following

its receipt of a COA in accordance with this Section 6.3(a), Manufacturer shall

have the right to ship the Product on the scheduled Product shipment date.

 

                  (b) Notwithstanding any termination or expiration of this

Supply Agreement, Manufacturer shall keep manufacturing and quality control

documentation as well as sufficient and representative retained samples of the

Product ("Retained Samples") and perform stability testing with respect to

Product sold to AAI in compliance with CGMP Requirements and other applicable

Law. Manufacturer and AAI shall agree upon a reasonable amount of Retained

Samples to be maintained for this purpose. Manufacturer's obligations under this

Section 6.3(b) with respect to a Retained Sample and stability testing shall

remain in effect for the period required by applicable Law.

 

                  (c) Manufacturer shall, at Manufacturer's expense, make

available for review by AAI, at any reasonable time upon reasonable notice,

manufacturing and analytical information related to the Product, including

written investigations of any deviations that may have occurred during the

Manufacturing or inspection of, or testing processes related to, the Product.

 

                  (d) Manufacturer is solely responsible for the safety of its

employees.

 

         6.4 Non-Conforming Product. Notwithstanding anything in this Supply

Agreement to the contrary, the Manufacturer shall not deliver to AAI any Product

which would constitute a breach of the representations and warranties set forth

in Section 5.1(g) of this Supply Agreement. In the event that any Product shall

fail to pass the quality control testing conducted by the Manufacturer, if any,

the Manufacturer shall provide the test results to the AAI and the Manufacturer

shall not release the Product Batch.

 

                                    ARTICLE 7

                           FORECASTS, ORDERS AND SALES

 

         7.1 Forecasting. Prior to the Qualification Date, AAI shall provide

Manufacturer with a written good faith forecast estimating AAI's quarterly

requirements (broken out on a month-to-month basis) of the Product for each of

the first twelve (12) calendar quarters beginning on the Qualification Date.

Thereafter, not later than sixty (60) days prior to the commencement of each

subsequent calendar quarter during the Term, AAI shall provide Manufacturer with

rolling eight (8) quarter forecasts (broken out on a month-to-month basis) that

shall cover the succeeding eight (8) quarter period (or the period until the

expiration of the Term, if shorter) (such forecast, as updated from time to

time, shall hereinafter be referred to as the "Long-Term Forecast"). Except as

set forth in Sections 7.2(a) and 7.2(b), the Long-Term Forecast shall not be

binding on either Party, but beginning on the Supply Start Date, the


SITE SEARCH

AGREEMENTS / CONTRACTS

Document Title:

Entire Document: (optional)

Governing Law:(optional)
 

CLAUSES

Search Contract Clauses >>

Browse Contract Clause Library>>

Close this window